139 related articles for article (PubMed ID: 3273618)
1. Overview of currently available Japanese acellular pertussis vaccines and future problems.
Kamiya H; Nii R
Tokai J Exp Clin Med; 1988; 13 Suppl():45-9. PubMed ID: 3273618
[TBL] [Abstract][Full Text] [Related]
2. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
3. Japanese clinical trials with Takeda acellular pertussis vaccine.
Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
[TBL] [Abstract][Full Text] [Related]
4. Results with a new DTP vaccine in Japan.
Kimura M; Hikino N
Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies on efficacy and safety of acellular pertussis vaccine.
Isomura S
Tokai J Exp Clin Med; 1988; 13 Suppl():39-43. PubMed ID: 3078809
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups.
Cherry JD; Mortimer EA; Hackell JG; Scott JV
Dev Biol Stand; 1991; 73():51-8. PubMed ID: 1778334
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of acellular pertussis vaccine in Japan--comparison of two areas, one area where immunization started at 6 months and the other area at over 2 years of age--Regional Surveillance Committee on Tuberculosis and Infectious Diseases of Osaka.
Ohkuni H; Kitaura T; Tamai T; Takasugi Y; Sugimoto T; Fukai K
Tokai J Exp Clin Med; 1988; 13 Suppl():51-4. PubMed ID: 3273619
[TBL] [Abstract][Full Text] [Related]
8. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
9. Preliminary report on household contact studies of the prevention of pertussis in Japanese children by Takeda diphtheria and tetanus toxoids and acellular pertussis vaccine combined.
Mortimer EA
Tokai J Exp Clin Med; 1988; 13 Suppl():29-34. PubMed ID: 3078807
[TBL] [Abstract][Full Text] [Related]
10. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.
Feldman S; Perry CS; Andrew M; Jones L; Moffitt JE; Lamb D; Meschievitz C
South Med J; 1993 Mar; 86(3):269-75, 284. PubMed ID: 8451663
[TBL] [Abstract][Full Text] [Related]
11. Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at 2, 4, and 6 months of age.
Rothstein EP; Kamiya H; Nii R; Matsuda T; Bernstein HH; Long SS; Hosbach PH; Meschievitz CK
Pediatrics; 1996 Feb; 97(2):236-42. PubMed ID: 8584384
[TBL] [Abstract][Full Text] [Related]
12. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
[TBL] [Abstract][Full Text] [Related]
13. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
Kuno-Sakai H; Kimura M; Watanabe H
Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
[TBL] [Abstract][Full Text] [Related]
14. Protection against pertussis by Takeda's acellular pertussis vaccine: household contact studies in Kawasaki City, Japan.
Kato T; Kaku H; Arimoto Y
Tokai J Exp Clin Med; 1988; 13 Suppl():35-8. PubMed ID: 3078808
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants.
Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA; Meschievitz C
Pediatrics; 1993 Apr; 91(4):756-60. PubMed ID: 8464662
[TBL] [Abstract][Full Text] [Related]
16. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
17. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
18. Role of whole-cell pertussis vaccine in severe local reactions to the preschool (fifth) dose of diphtheria-pertussis-tetanus vaccine.
Scheifele DW; Bjornson G; Halperin SH; Mitchell L; Boraston S
CMAJ; 1994 Jan; 150(1):29-35. PubMed ID: 8275406
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of pertussis in Japan.
Kimura M; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():1-7. PubMed ID: 3273609
[No Abstract] [Full Text] [Related]
20. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan.
Sato H; Sato Y
Clin Infect Dis; 1999 Jun; 28 Suppl 2():S124-30. PubMed ID: 10447030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
